If Fidelity is your brokerage, you can click on "Analyst Opinions" and that will bring up all the institution advisors' opinions for AMOT.
PPS will go up shortly. Four institution advisors have BUY or STRONG BUY ratings and Institutions are accumulating.
Allied Motion Technologies Inc. (AMOT) today announced net income increased 39% to $2,976,000 or $0.32 per diluted share for the quarter ended March 31, 2015 compared to $2,148,000 or $0.24 per diluted share for the quarter ended March 31, 2014. Revenues for the quarter declined 1% to $59,580,000 compared to $60,435,000 last year with the decline resulting from the strengthening of the U.S. dollar against foreign currencies. Sales volumes for the quarter were up over last year by 6%, while the currency impact reduced sales by 7%.
Despite the currency issue, the company still outperformed.
"A unique longer-term potential for Inotek is that pre-clinical work indicates that trabodenoson may protect the nerve tissue in the retina that relays the visual signal to the brain. Thus Inotek's trabodenoson may have a novel mode of action to prevent vision loss beyond that of the IOP-lowering effect alone, which is the mode of action of all existing glaucoma medications."
In that sense, ITEK's trabodenoson is potentially better than AERI's lead candidate, or any other glaucoma medications currently on the market.
Oncolytics has a period of 180-calendar days, or until April 27, 2015, to regain compliance with the minimum bid price requirement. When at any time during the 180-day period, the minimum closing bid price per share of the Company's common stock closes at or above $1.00 for a minimum of ten consecutive business days, Oncolytics will regain compliance and the matter will be closed.
09:29 AM EST, 03/02/2015 (MT Newswires) -- Weight Watchers ( WTW) shares were downgraded by Morgan Stanley to underweight from equal weight, and the firm lowered its price target to $9 from $24.